// App-Quantinova.ai

: Efficacy of targeted therapy (TT) after checkpoint inhibitors (CPI) in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer Information System (CKCis).

Researchers

Presenter

  • Austin Kalirai

Principal Investigators

  • Lori Wood

  • Aly-Khan A. Lalani

  • Daniel Yick Chin Heng

  • Sunita Ghosh

  • Marco Adelmo James Iafolla

  • Christian K. Kollmannsberger

  • Denis Soulieres

  • Vincent Castonguay

  • Dominick Boss

  • Eric Winquist

  • Anil Kapoor

  • Naveen S. Basappa

Medical Centers

  • University of Alberta, Edmonton, AB, Canada

  • Dalhousie University, Halifax, Nova Scotia, Canada.

  • Juravinski Cancer Centre and McMaster University, Hamilton, ON, Canada

  • University of Calgary, Calgary, AB, Canada

  • Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada

  • University of Alberta, Edmonton, AB, Canada

  • The University of British Columbia, Vancouver, BC, Canada

  • Centre Hospitalier de LUniversite de Montreal (CHUM), Montreal, QC, Canada

  • Hotel-Dieu de Quebec, Quebec, Quebec, Canada

  • Ottawa Hospital Cancer Centre, Ottawa, ON, Canada

  • Western University and London Health Sciences Centre, London, ON, CA

  • Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

Disease

  • Metastatic Renal Cell Cancer

  • Renal cell carcinoma

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved